109 related articles for article (PubMed ID: 15496978)
1. The novel histone deacetylase inhibitor NVP-LAQ824: an addition to the therapeutic armamentarium in leukemia?
Grant S
Leukemia; 2004 Dec; 18(12):1931-3. PubMed ID: 15496978
[No Abstract] [Full Text] [Related]
2. Histone deacetylase inhibitor NVP-LAQ824 has significant activity against myeloid leukemia cells in vitro and in vivo.
Weisberg E; Catley L; Kujawa J; Atadja P; Remiszewski S; Fuerst P; Cavazza C; Anderson K; Griffin JD
Leukemia; 2004 Dec; 18(12):1951-63. PubMed ID: 15496979
[TBL] [Abstract][Full Text] [Related]
3. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
Qian DZ; Wang X; Kachhap SK; Kato Y; Wei Y; Zhang L; Atadja P; Pili R
Cancer Res; 2004 Sep; 64(18):6626-34. PubMed ID: 15374977
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells.
Nimmanapalli R; Fuino L; Bali P; Gasparetto M; Glozak M; Tao J; Moscinski L; Smith C; Wu J; Jove R; Atadja P; Bhalla K
Cancer Res; 2003 Aug; 63(16):5126-35. PubMed ID: 12941844
[TBL] [Abstract][Full Text] [Related]
5. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies.
Giles F; Fischer T; Cortes J; Garcia-Manero G; Beck J; Ravandi F; Masson E; Rae P; Laird G; Sharma S; Kantarjian H; Dugan M; Albitar M; Bhalla K
Clin Cancer Res; 2006 Aug; 12(15):4628-35. PubMed ID: 16899611
[TBL] [Abstract][Full Text] [Related]
6. Selective growth inhibition of tumor cells by a novel histone deacetylase inhibitor, NVP-LAQ824.
Atadja P; Gao L; Kwon P; Trogani N; Walker H; Hsu M; Yeleswarapu L; Chandramouli N; Perez L; Versace R; Wu A; Sambucetti L; Lassota P; Cohen D; Bair K; Wood A; Remiszewski S
Cancer Res; 2004 Jan; 64(2):689-95. PubMed ID: 14744786
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibitors in cancer therapy.
Fouladi M
Cancer Invest; 2006; 24(5):521-7. PubMed ID: 16939962
[No Abstract] [Full Text] [Related]
8. Histone deacetylase inhibitors: development of suberoylanilide hydroxamic acid (SAHA) for the treatment of cancers.
Richon VM; Zhou X; Rifkind RA; Marks PA
Blood Cells Mol Dis; 2001; 27(1):260-4. PubMed ID: 11358386
[No Abstract] [Full Text] [Related]
9. Molecular and cellular basis for the anti-proliferative effects of the HDAC inhibitor LAQ824.
Atadja P; Hsu M; Kwon P; Trogani N; Bhalla K; Remiszewski S
Novartis Found Symp; 2004; 259():249-66; discussion 266-8, 285-8. PubMed ID: 15171259
[TBL] [Abstract][Full Text] [Related]
10. A new class of anti-cancer drugs: HDAC-inhibitors.
Pelicci PG
Suppl Tumori; 2002; 1(4):S66. PubMed ID: 12415827
[No Abstract] [Full Text] [Related]
11. Use of a novel histone deacetylase inhibitor to induce apoptosis in cell lines of acute lymphoblastic leukemia.
Romanski A; Bacic B; Bug G; Pfeifer H; Gul H; Remiszewski S; Hoelzer D; Atadja P; Ruthardt M; Ottmann OG
Haematologica; 2004 Apr; 89(4):419-26. PubMed ID: 15075075
[TBL] [Abstract][Full Text] [Related]
12. Molecular therapeutic approaches to acute myeloid leukemia: targeting aberrant chromatin dynamics and signal transduction.
Piazza F; Semenzato G
Expert Rev Anticancer Ther; 2004 Jun; 4(3):387-400. PubMed ID: 15161438
[TBL] [Abstract][Full Text] [Related]
13. Molecule of the month. Vorinostat.
Drug News Perspect; 2006; 19(6):352. PubMed ID: 16971971
[No Abstract] [Full Text] [Related]
14. Novel agents in acute myeloid leukemia.
Aribi A; Ravandi F; Giles F
Cancer J; 2006; 12(2):77-91. PubMed ID: 16630396
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors.
Bradbury CA; Khanim FL; Hayden R; Bunce CM; White DA; Drayson MT; Craddock C; Turner BM
Leukemia; 2005 Oct; 19(10):1751-9. PubMed ID: 16121216
[TBL] [Abstract][Full Text] [Related]
16. Belinostat: a new broad acting antineoplastic histone deacetylase inhibitor.
Gimsing P
Expert Opin Investig Drugs; 2009 Apr; 18(4):501-8. PubMed ID: 19335278
[TBL] [Abstract][Full Text] [Related]
17. Acute myeloid leukemia: therapeutic impact of epigenetic drugs.
Altucci L; Clarke N; Nebbioso A; Scognamiglio A; Gronemeyer H
Int J Biochem Cell Biol; 2005 Sep; 37(9):1752-62. PubMed ID: 15964234
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells.
Yu C; Rahmani M; Almenara J; Subler M; Krystal G; Conrad D; Varticovski L; Dent P; Grant S
Cancer Res; 2003 May; 63(9):2118-26. PubMed ID: 12727828
[TBL] [Abstract][Full Text] [Related]
19. Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of a novel histone deacetylase inhibitor, LAQ824, in human colon carcinoma cells and xenografts.
Chung YL; Troy H; Kristeleit R; Aherne W; Jackson LE; Atadja P; Griffiths JR; Judson IR; Workman P; Leach MO; Beloueche-Babari M
Neoplasia; 2008 Apr; 10(4):303-13. PubMed ID: 18392140
[TBL] [Abstract][Full Text] [Related]
20. G1 cell-cycle arrest and apoptosis by histone deacetylase inhibition in MLL-AF9 acute myeloid leukemia cells is p21 dependent and MLL-AF9 independent.
Tonelli R; Sartini R; Fronza R; Freccero F; Franzoni M; Dongiovanni D; Ballarini M; Ferrari S; D'Apolito M; Di Cola G; Capranico G; Khobta A; Campanini R; Paolucci P; Minucci S; Pession A
Leukemia; 2006 Jul; 20(7):1307-10. PubMed ID: 16617320
[No Abstract] [Full Text] [Related]
[Next] [New Search]
